<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To increase the valency, stability, and therapeutic potential of bispecific antibodies, we have constructed a tetravalent tandem diabody (Tandab) that is specific to both human CD3 (T-cell antigen) and CD19 (B-cell marker; S </plain></SENT>
<SENT sid="1" pm="."><plain>M </plain></SENT>
<SENT sid="2" pm="."><plain>Kipriyanov et al., J </plain></SENT>
<SENT sid="3" pm="."><plain>Mol </plain></SENT>
<SENT sid="4" pm="."><plain>Biol., 293: 41-56, 1999) </plain></SENT>
<SENT sid="5" pm="."><plain>It was generated by the functional dimerization of a single chain molecule that contained four antibody variable domains (V(H) and V(L)) in an orientation that prevented intramolecular pairing </plain></SENT>
<SENT sid="6" pm="."><plain>Compared with a previously constructed heterodimeric CD3 x CD19 diabody, the Tandab exhibited a higher apparent affinity to both CD3+ and CD19+ cells and longer blood retention when injected into mice </plain></SENT>
<SENT sid="7" pm="."><plain>Biodistribution studies in mice bearing Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> xenografts demonstrated specific accumulation of the radioiodinated Tandab in a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> site with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-to-blood ratios of 1.5, 8.1, and 13.3 at 3, 18, and 24 h, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Treatment of <z:hpo ids='HP_0004430'>severe combined immunodeficiency</z:hpo> mice bearing established Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (5 mm in diameter) with human peripheral blood lymphocytes, Tandab, and anti-CD28 MAbs resulted in the complete elimination of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in <z:hpo ids='HP_0000001'>all</z:hpo> of the animals within 10 days </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast, mice receiving human peripheral blood lymphocytes in combination with either the diabody alone or the diabody plus anti-CD28 MAbs showed only partial <z:mp ids='MP_0010537'>tumor regression</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>These data demonstrate that the CD3 x CD19 Tandab may be a promising tool for the immunotherapy of human B-cell <z:hpo ids='HP_0001909'>leukemias</z:hpo> and <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>